<DOC>
	<DOCNO>NCT00253123</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy risperidone ( antipsychotic medication ) versus placebo treatment behavioral disturbance associate dementia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Versus Placebo Treatment Behavioral Disturbances Patients With Dementia</brief_title>
	<detailed_description>Dementia term use collection symptom cause number disease injury affect brain . Individuals dementia loss cognitive function ( think , perception , learning , verbal communication , memory , judgment ) , may lead behavioral personality change ( example , agitation , delusion , hallucination ) . Some cause dementia reversible ; however , irreversible dementia cause certain condition , Alzheimer 's disease . Dementia common elderly individual , normal part age . This randomized , double-blind , parallel-group , placebo-controlled study compare effectiveness safety risperidone placebo patient behavioral disturbance associate dementia . The study compose screen visit , follow two study phase : 1-week run-in period patient discontinue antipsychotic drug receive placebo twice daily , 12-week double-blind period . At end run-in period , patient randomly assign one three risperidone dos ( 0.5 , 1 , 2 mg/day ) placebo . All patient randomize risperidone start 0.25 mg twice daily . During first week double-blind period , patient assign 1 mg/day dose group dos increase 0.5 mg twice daily patient assign 2 mg/day dose group dos increase 1 mg twice daily . These three assign dos continue additional 11 week . The primary measure effectiveness change baseline clinical response , define reduction &gt; = 30 % baseline total Behavior Pathology Alzheimer 's Disease Rating Scale ( BEHAVE-AD ) score . Additional efficacy test include Clinical Global Impressions ( CGI ) , rating system use evaluate overall severity clinical change patient various disease affect brain ; Cohen-Mansfield Agitation Inventory ( CMAI ) , questionnaire evaluate agitation complete patient 's caregiver ; Physical Self-Maintenance Scale ( PSMS ) , scale measure activity daily live ( example , toileting , dress , groom , feeding , etc. ) . Safety evaluation include incidence adverse event ; result clinical laboratory test ( hematology , biochemistry , urinalysis ) ; measurement vital sign ; physical examination electrocardiogram ( ECG ) finding ; Extrapyramidal Symptoms Rating Scale ( ESRS ) , scale use measure effect antipsychotic medication motor function patient . The study hypothesis risperidone effective placebo , measure change baseline total BEHAVE-AD score , treat behavioral disturbance demented patient . Risperidone tablet ( placebo tablet ) take orally , start 0.25 mg twice daily , continue dose 0.25 twice daily group gradually increase either 0.5 mg twice daily 1 mg twice daily risperidone dose group . Treatment duration 12 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Problem Behavior</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patients diagnosis dementia Alzheimer 's type , mixed dementia , vascular dementia , classify Diagnostic Statistical Manual Mental Diseases , 4th edition ( DSMIV ) score 4 Functional Assessment Staging ( FAST ) , diagnostic tool determine stage dementia score 23 low MiniMental State Examination ( MMSE ) , clinical measure use evaluate cognition BEHAVEAD total score least 8 , BEHAVEAD global rating least 1 residence psychiatric hospital , nursing home , longterm care facility least 1 month . Patients untreated , reversible cause dementia general medical neurological condition cognition diminish ( example , untreated vitamin deficiency , severe liver kidney malfunction , brain tumor , etc . ) dementia relate HIV infection ( human immunodeficiency virus ) substanceinduced persist dementia psychiatric disorder could account behavior disturbance , schizophrenia .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>vascular dementia</keyword>
	<keyword>mixed dementia</keyword>
	<keyword>risperidone</keyword>
	<keyword>nursing home</keyword>
</DOC>